Peptides for Nerve Repair & Peripheral Neuropathy

Nerve damage remains one of the most challenging clinical problems in medicine. Peripheral nerves can regenerate, but they do so slowly (approximately 1 mm per day) and often incompletely. Central nervous system neurons have even more limited regenerative capacity. The search for agents that accelerate nerve repair, protect surviving neurons, and restore function has led researchers to investigate several peptides that modulate neurotrophic signaling, angiogenesis, and neuroinflammation.

This guide examines the peptides most actively researched for nerve repair and neuroprotection, with an honest assessment of where the evidence stands.

The Biology of Nerve Repair

Peripheral Nerve Regeneration

When a peripheral nerve is injured, a sequence called Wallerian degeneration occurs in the segment distal to the injury. The axon and myelin sheath degenerate, Schwann cells dedifferentiate and begin clearing debris (along with macrophages), and the basement membrane tubes (bands of Bungner) form a scaffold for axonal regrowth. Schwann cells upregulate neurotrophic factors — nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and others — that guide regenerating axon sprouts back toward their targets.

The rate-limiting steps in peripheral nerve regeneration are:

1. Axonal sprouting initiation — the proximal stump must form growth cones
2. Growth cone navigation — sprouts must find and follow the Schwann cell tubes
3. Myelination — Schwann cells must re-myelinate the regenerating axons
4. Target reinnervation — axons must reconnect with appropriate end organs (muscle, skin, glands)
5. Functional maturation — regenerated connections must refine and mature

Peptides that accelerate any of these steps have therapeutic potential.

Central Nervous System Challenges

CNS neurons face additional barriers to regeneration: inhibitory myelin-associated proteins (Nogo, MAG, OMgp), astrocytic scar tissue (glial scar), and an inflammatory environment that is hostile to axonal growth. Peptides targeting CNS repair must address these inhibitory signals in addition to promoting growth.

Neurotrophic Factors: The Key Targets

Most neuroregenerative peptides work by modulating neurotrophic factor signaling:

• NGF (Nerve Growth Factor): Supports sensory and sympathetic neurons
• BDNF (Brain-Derived Neurotrophic Factor): Supports motor neurons, sensory neurons, and CNS neurons; critical for synaptic plasticity
• GDNF (Glial Cell-Derived Neurotrophic Factor): Supports motor neurons and dopaminergic neurons
• CNTF (Ciliary Neurotrophic Factor): Supports motor neurons and oligodendrocytes
• HGF (Hepatocyte Growth Factor): Neuroprotective and neurogenic; HGF/c-Met signaling promotes neurite outgrowth

BPC-157: The Tissue Repair Peptide with Neurotrophic Properties

Mechanism of Action in Nerve Repair

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein in human gastric juice. Its neuroregenerative mechanisms include:

Neurotrophic factor upregulation. BPC-157 has been shown to increase expression of NGF, BDNF, and their receptors (TrkA, TrkB) in injured nerve tissue in preclinical models. This upregulation accelerates Schwann cell-mediated repair processes.

Angiogenesis. BPC-157 promotes new blood vessel formation through VEGF upregulation and eNOS/NO system activation. Nerve regeneration is heavily dependent on revascularization — axonal regrowth follows new blood vessel growth, and ischemic conditions severely impair nerve repair.

Anti-inflammatory effects. BPC-157 modulates the inflammatory response at injury sites, reducing excessive inflammation that can impair regeneration while preserving the beneficial inflammatory signals that recruit repair cells.

GABAergic system modulation. BPC-157 interacts with the GABAergic system and has been shown to modulate dopamine and serotonin turnover, which may contribute to its effects on central neuroprotection.

Nitric oxide system. BPC-157 interacts with the NO system in multiple ways, functioning as both an NO system stabilizer and interacting with the NO-cGMP pathway. This is relevant because NO signaling plays a role in neural plasticity and regeneration.

Preclinical Evidence for Nerve Repair

The preclinical data on BPC-157 and nerve repair is extensive and comes primarily from a single research group (Sikiric et al., University of Zagreb):

Sciatic nerve crush injury. In rat models of sciatic nerve crush, BPC-157 (administered intraperitoneally or locally) accelerated functional recovery as measured by sciatic functional index (SFI), electromyography, and histological assessment of axonal regeneration and myelination.

Sciatic nerve transection. In more severe models (complete nerve cut), BPC-157 improved functional outcomes compared to controls, though the effect size was smaller than in crush injuries, consistent with the greater biological challenge of regeneration across a transection gap.

Cerebral ischemia. In stroke models, BPC-157 reduced infarct volume and improved neurological deficit scores, suggesting central neuroprotective effects.

Traumatic brain injury. BPC-157 reduced brain edema, improved blood-brain barrier integrity, and improved behavioral outcomes in TBI models.

Peripheral neuropathy models. BPC-157 showed protective effects against cuprizone-induced demyelination and improved outcomes in models of toxic neuropathy.

Clinical Evidence

This is where the assessment becomes more cautious. As of 2026, there are no published randomized controlled trials of BPC-157 for nerve repair or neuropathy in humans. The preclinical data is promising but derives predominantly from a single research group, which raises the usual concerns about independent replication.

Anecdotal reports from clinical use (administered by practitioners in compounding pharmacy settings) describe improvements in neuropathy symptoms, reduced nerve pain, and faster recovery from nerve injuries. These reports are informative but do not constitute controlled evidence.

Evidence quality assessment: Strong preclinical rationale. Extensive animal data showing consistent effects across multiple nerve injury models. No controlled human data specific to nerve repair. The mechanism of action is biologically plausible and involves well-characterized neurotrophic pathways.

Cerebrolysin: Neurotrophic Factor Mimetic

What Is Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from enzymatic breakdown of porcine brain protein. It contains a complex mixture of neurotrophic and neuroprotective peptide fragments, including fragments that mimic the activity of BDNF, NGF, GDNF, and CNTF.

Unlike the other peptides in this guide, Cerebrolysin is not a single defined molecule — it is a standardized biological preparation with a consistent peptide profile but inherent complexity.

Mechanism of Action

Neurotrophic mimicry. The peptide fragments in Cerebrolysin activate Trk receptors (TrkA, TrkB) and other neurotrophic signaling pathways similarly to native neurotrophic factors, but with the advantage of being small enough to cross the blood-brain barrier (native NGF and BDNF are too large for CNS delivery).

Anti-apoptotic effects. Cerebrolysin activates PI3K/Akt survival signaling and inhibits caspase-mediated apoptosis in neurons, protecting against delayed neuronal death after injury.

Synaptic plasticity. Cerebrolysin modulates synaptic protein expression (synaptophysin, PSD-95) and enhances long-term potentiation (LTP), the molecular basis of memory formation.

Neurogenesis. Cerebrolysin has been shown to stimulate neural stem cell proliferation and differentiation in the subventricular zone and hippocampus in animal models.

Clinical Evidence

Cerebrolysin has the most extensive clinical evidence of any peptide in this guide for neurological applications, though primarily in stroke and dementia rather than peripheral neuropathy.

Stroke: Multiple RCTs have evaluated Cerebrolysin in acute ischemic stroke. The CASTA (Cerebrolysin in Acute STroke in Asia) trial and other studies have shown mixed results. A Cochrane review found insufficient evidence to recommend routine use, though some trials showed improvements in specific neurological outcome measures. The E-COMPASS trial showed benefits in early neurological improvement when Cerebrolysin was combined with rehabilitation.

Alzheimer's disease: RCTs have demonstrated improvements in cognitive function scores (ADAS-cog) over 6-month treatment periods. The effect sizes are modest and comparable to cholinesterase inhibitors.

Traumatic brain injury: A large multicenter RCT (CAPTAIN) showed improvements in cognitive and functional outcomes at 90 days in patients with moderate to severe TBI receiving Cerebrolysin.

Peripheral neuropathy: Limited clinical data. Case series and small studies suggest potential benefits in diabetic neuropathy (improvement in nerve conduction velocity and symptom scores), but large RCTs are lacking.

Evidence quality assessment: Strong for central neuroprotection (multiple RCTs, though with mixed results). Limited for peripheral nerve repair. The product is approved in over 40 countries (primarily in Europe and Asia) for neurological indications but has not received FDA approval.

Semax: Nootropic and Neuroprotective Peptide

What Is Semax

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment Methionyl-Glutamyl-Histidyl-Phenylalanyl-Prolyl-Glycyl-Proline. It was developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and is approved in Russia as a nootropic and neuroprotective drug.

Mechanism of Action in Nerve Repair

BDNF upregulation. Semax is one of the most potent pharmacological inducers of BDNF expression identified. In animal studies, Semax administration increases BDNF mRNA and protein levels in the hippocampus and cortex by 200 to 800% within hours of administration. This magnitude of BDNF induction is remarkable for a synthetic peptide.

NGF modulation. Semax increases NGF expression in specific brain regions, providing additional neurotrophic support.

Neurotrophin receptor activation. By increasing endogenous neurotrophin levels, Semax indirectly activates TrkB (BDNF receptor) and TrkA (NGF receptor) signaling cascades involved in neuronal survival, axonal growth, and synaptic plasticity.

Immunomodulation. Semax modulates the expression of immune-related genes in the brain, reducing neuroinflammation while preserving beneficial immune surveillance. Transcriptomic studies have identified changes in hundreds of genes related to immune function, vascular regulation, and cell survival.

Serotonin and dopamine modulation. Semax influences monoaminergic neurotransmission, which may contribute to its nootropic and mood-modulating effects.

Preclinical Evidence for Nerve Repair

Ischemic brain injury. In models of focal cerebral ischemia, Semax reduced infarct volume by 25 to 40%, improved neurological deficit scores, and increased survival of neurons in the penumbral zone. The neuroprotective effect was associated with BDNF and NGF upregulation and modulation of inflammatory gene expression.

Optic nerve damage. Semax accelerated regeneration of retinal ganglion cell axons after optic nerve crush in rats, an effect attributed to BDNF-mediated neurotrophic support.

Neurodegenerative models. Semax showed protective effects in models of MPTP-induced dopaminergic neuron loss (Parkinson's model) and in models of cognitive impairment.

Clinical Evidence

Stroke: Semax is approved in Russia for the treatment of acute ischemic stroke. Clinical studies (conducted primarily in Russian institutions) have reported improvements in neurological recovery, cognitive function, and functional outcomes. The quality of these trials by Western evidence standards is variable, and the data has not been independently replicated in Western clinical trials.

Cognitive enhancement: Multiple Russian clinical studies report cognitive improvements in patients with cerebrovascular disease, ADHD, and post-stroke cognitive impairment.

Peripheral neuropathy: No published clinical trials specifically for peripheral neuropathy. The theoretical basis for peripheral nerve repair rests on the BDNF and NGF upregulation data.

Evidence quality assessment: Strong preclinical data for neurotrophic factor induction and central neuroprotection. Clinical evidence exists but is primarily from Russian studies that have not undergone independent replication in Western trial frameworks. No controlled human data for peripheral neuropathy.

Selank: Anxiolytic with Neuroprotective Properties

What Is Selank

Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with an additional Pro-Gly-Pro sequence. Like Semax, it was developed at the Institute of Molecular Genetics in Russia and is approved there as an anxiolytic.

Mechanism of Action

BDNF modulation. Like Semax, Selank upregulates BDNF expression, though the magnitude and kinetics differ. Selank's BDNF effects appear to be more sustained and moderate compared to Semax's acute, high-magnitude induction.

GABAergic modulation. Selank modulates GABAergic neurotransmission, which underlies its anxiolytic effects but also contributes to neuroprotection by reducing excitotoxicity.

Enkephalinase inhibition. Selank inhibits enzymes that degrade enkephalins (endogenous opioid peptides), which has implications for pain modulation in neuropathic conditions.

Immunomodulation. As a tuftsin analog, Selank modulates innate and adaptive immune function, influencing cytokine profiles and immune cell activity. This immunomodulatory activity may be relevant for autoimmune neuropathies where immune-mediated nerve damage is the primary pathology.

Gene expression modulation. Transcriptomic studies have shown that Selank influences the expression of over 40 genes related to immune function, neurotransmission, and neuroplasticity.

Relevance to Nerve Repair

Selank's primary relevance to neuropathy is threefold:

1. Neuropathic pain. The enkephalinase inhibition and GABAergic modulation may reduce neuropathic pain signaling. Neuropathic pain is often the most debilitating aspect of peripheral neuropathy, and agents that address it without the tolerance and dependence issues of opioids are clinically valuable.
2. Neuroinflammation reduction. In autoimmune and inflammatory neuropathies (such as chronic inflammatory demyelinating polyneuropathy), Selank's immunomodulatory properties could theoretically reduce the immune-mediated damage.
3. BDNF-mediated neurotrophic support. The BDNF upregulation provides general neurotrophic support for surviving neurons and may support regenerative processes.

Clinical Evidence

Selank is approved in Russia as a nasal spray for anxiety and neurasthenia. Clinical studies (Russian) report anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or dependence. No published clinical trials exist for peripheral neuropathy or nerve repair.

Evidence quality assessment: Moderate preclinical data for neuroprotective effects. Clinical evidence limited to anxiolytic applications in Russian studies. The neuropathy application is extrapolated from mechanism-of-action data rather than direct evidence.

Dihexa: The Potent HGF/c-Met Modulator

What Is Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a modified hexapeptide fragment of angiotensin IV that was developed at Washington State University. It is one of the most potent neurotrophic compounds identified in preclinical research, active at picomolar concentrations (roughly 10 million times more potent than BDNF in promoting neurite outgrowth in cell culture).

Mechanism of Action

HGF/c-Met pathway potentiation. Dihexa's primary mechanism is potentiation of hepatocyte growth factor (HGF) signaling through the c-Met receptor. HGF/c-Met signaling promotes:

• Neurite outgrowth and branching
• Neuronal survival
• Synaptogenesis
• Angiogenesis in neural tissue
• Axonal regeneration

Dihexa does not directly activate c-Met. Instead, it stabilizes the HGF/c-Met interaction, potentiating the effects of endogenous HGF. This is mechanistically distinct from direct neurotrophic factor administration and may avoid some of the dosing and delivery challenges.

Dimerization facilitation. Dihexa may facilitate HGF dimerization, which is required for full c-Met activation. This would explain its ability to amplify HGF signaling even at very low concentrations.

Preclinical Evidence

Cognitive enhancement. In aged rats and in scopolamine-induced cognitive impairment models, Dihexa restored cognitive performance to levels comparable to young animals. The effect was dose-dependent and observed at very low doses (oral and subcutaneous administration).

Spinogenesis. Dihexa increased dendritic spine density in hippocampal neurons, suggesting direct effects on synaptogenesis and neural connectivity.

Neurite outgrowth. In cell culture, Dihexa promoted neurite outgrowth at picomolar concentrations, making it the most potent pro-neuritogenic compound characterized.

Dementia models. In multiple models of cognitive impairment (age-related, scopolamine-induced, and Alzheimer's transgenic models), Dihexa improved memory and learning.

Relevance to Nerve Repair

Dihexa's relevance to peripheral nerve repair is primarily through HGF/c-Met signaling. HGF is expressed by Schwann cells and is upregulated after peripheral nerve injury. It promotes Schwann cell migration, axonal regrowth, and revascularization of injured nerve segments. A compound that potentiates HGF signaling could theoretically accelerate multiple aspects of peripheral nerve regeneration.

However, no published studies have specifically tested Dihexa in peripheral nerve injury models. The neuroregeneration evidence is derived from CNS models (hippocampal neurons, cognitive function) rather than peripheral nerve models.

Safety Considerations

Dihexa's extraordinary potency raises safety questions. HGF/c-Met signaling is implicated in multiple cancers (the c-Met pathway is an oncogene). While short-term potentiation of HGF signaling for nerve repair may not pose cancer risk, the long-term safety implications of chronic c-Met pathway activation are unknown and theoretically concerning.

Evidence quality assessment: Strong preclinical data for neurotrophic activity in CNS models. No peripheral nerve-specific data. No human clinical trials. Theoretical cancer risk concerns from chronic use. The most mechanistically promising but least clinically validated compound in this guide.

Comparing the Peptides

Evidence Strength Ranking

1. Cerebrolysin — Multiple RCTs, approved in 40+ countries, most clinical data
2. Semax — Approved in Russia, multiple clinical studies, strong preclinical neurotrophic data
3. BPC-157 — Extensive preclinical data across nerve injury models, no RCTs
4. Selank — Approved in Russia for anxiolysis, limited nerve-specific data
5. Dihexa — Potent preclinical neurotrophic activity, no clinical data

Mechanism Comparison

Peptide	Primary Mechanism	BDNF Effect	NGF Effect	Anti-inflammatory	Route
BPC-157	Multi-pathway (VEGF, NO, neurotrophins)	Upregulation	Upregulation	Yes	SC, oral
Cerebrolysin	Neurotrophic factor mimicry	TrkB activation	TrkA activation	Moderate	IV, IM
Semax	BDNF/NGF gene induction	Strong upregulation	Upregulation	Yes	Intranasal
Selank	GABA/enkephalin/immune modulation	Moderate upregulation	Indirect	Yes	Intranasal
Dihexa	HGF/c-Met potentiation	Indirect	Indirect	Unknown	SC, oral

Practical Considerations

What Neuropathy Patients Should Know

Peripheral neuropathy has multiple etiologies: diabetic, chemotherapy-induced, idiopathic, autoimmune, traumatic, compressive, and toxic. The underlying cause significantly influences which therapeutic approach is appropriate.

Diabetic neuropathy is primarily a metabolic and microvascular injury. Peptides that improve vascularization (BPC-157) and provide neurotrophic support (Cerebrolysin, Semax) are mechanistically relevant, but glucose control remains the primary intervention.

Chemotherapy-induced neuropathy involves direct neuronal toxicity. Neuroprotective peptides (Cerebrolysin, Semax) have theoretical utility in protecting against or recovering from chemotherapeutic nerve damage.

Traumatic nerve injury involves physical disruption of nerve fibers. BPC-157's multi-modal tissue repair mechanisms (angiogenesis, neurotrophic factor upregulation, anti-inflammation) are most directly relevant to this category.

Autoimmune neuropathies involve immune-mediated nerve damage. Selank's immunomodulatory properties are theoretically relevant here, though immunomodulatory treatments for these conditions already exist (IVIG, plasma exchange, corticosteroids).

The Limitations of Current Evidence

It is essential to be transparent about the limitations:

1. Most evidence is preclinical (animal models, cell culture)
2. The clinical data that exists is primarily for CNS applications, not peripheral neuropathy
3. Single-group research programs generate much of the data (particularly for BPC-157)
4. Independent replication in Western clinical trial frameworks is largely absent
5. Long-term safety data for chronic use in nerve repair is not available
6. Regulatory status varies by jurisdiction, and most of these peptides are not FDA-approved for any nerve-related indication

These peptides represent promising research directions, not established treatments. Individuals with neuropathy should work with qualified healthcare providers and should not substitute peptide therapy for established medical treatments. The decision to explore peptide therapy should be made with full awareness of the evidence limitations and in the context of comprehensive neuropathy management.

FAQ

What is the best peptide for nerve damage?

BPC-157 has the broadest preclinical evidence across nerve injury models — it upregulates NGF, VEGF, and promotes both central and peripheral nerve repair in animal studies. For central nervous system neuroprotection (stroke, TBI, neurodegenerative conditions), Cerebrolysin has the most clinical trial data, with RCTs in stroke recovery and Alzheimer's disease. The choice depends on whether the nerve damage is peripheral (BPC-157 is most relevant) or central (Cerebrolysin has stronger clinical support).

Can peptides help with diabetic neuropathy?

BPC-157 and Cerebrolysin have mechanistic rationale for diabetic neuropathy — BPC-157 through vascular repair (addressing the microvascular component) and Cerebrolysin through neurotrophic support (addressing neuronal degeneration). Limited clinical evidence exists specifically for diabetic neuropathy: Cerebrolysin has small studies showing improved nerve conduction velocity and symptom scores. However, glucose control remains the primary intervention — no peptide compensates for poorly managed blood sugar.

How long does it take for peptides to repair nerves?

Peripheral nerve regeneration is intrinsically slow — axons regrow at approximately 1-3 mm per day under optimal conditions. For a sciatic nerve injury at the hip, regeneration to the foot could take 12-18 months. Peptides may accelerate this rate and improve the quality of regeneration, but they do not bypass the biological speed limit of axonal growth. Most practitioners using BPC-157 for nerve injuries recommend minimum 8-12 week protocols, with assessment at 3-6 months for clinically meaningful neurological improvement.

Can you combine BPC-157 and Cerebrolysin for nerve repair?

Some practitioners combine BPC-157 (subcutaneous, targeting peripheral tissue repair) with Cerebrolysin (IV or IM, targeting central neurotrophic support) for complex nerve injuries. The rationale is that BPC-157 addresses the local tissue environment (vascularization, inflammation) while Cerebrolysin provides systemic neurotrophic factor support. No published study has tested this combination, so the approach is based on non-overlapping mechanisms rather than direct evidence. Timing is typically staggered — Cerebrolysin in intensive courses (10-20 days) with BPC-157 running continuously throughout.

Are nerve repair peptides safe with existing medications?

BPC-157, Semax, and Selank have no well-documented drug interactions with standard neuropathy medications (gabapentin, pregabalin, duloxetine, amitriptyline). Cerebrolysin is used clinically alongside conventional neurological medications in countries where it is approved. Dihexa is the most concerning for drug interactions due to its extraordinarily high potency and c-Met pathway effects — it should be approached with caution alongside any medication. Always inform treating physicians about peptide use, particularly if taking anticoagulants, immunosuppressants, or chemotherapy agents.